EyePoint Pharmaceuticals gained 19.10% on Wednesday. The Company's NDA for YUTIQ micro-insert, proposed for treatment of non-infectious posterior segment uveitis, is under FDA review - with a decision expected on November 5, 2018.
Original Article: EYPT Up 98% This Month, USNA In Good Health, MDXG To Report Q1 Results